Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reward-specific changes of cerebral dopamine synthesis in healthy volunteers and patients with major depressive disorder
2019-004880-33Phase 4Active
- Sponsor
- Medical University of Vienna
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of escitalopram and bupropion in major depressive disorder (MDD) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Reward-specific changes of dopamine synthesis. Started Jan 2023; status: active.
02
Drugs
escitaloprambupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-004880-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004880-33.